Polysomnographic features associated with clonazepam and melatonin treatment in isolated REM sleep behavior disorder: Time for new therapeutic approaches?
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14569 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Maria P Mogavero und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: REM Sleep Behavior Disorder, Melatonin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Aims
Although clonazepam (CLO) and melatonin (MLT) are the most frequently used treatments for REM sleep behavior disorder, the polysomnographic features associated with their use are little known. The aim of this study was to evaluate polysomnographic and clinical parameters of patients with idiopathic/isolated REM sleep behavior disorder (iRBD) treated chronically with CLO, sustained‐release MLT, alone or in combination, and in a group of drug‐free iRBD patients.
Methods
A total of 96 patients were enrolled: 43 drug‐free, 21 with CLO (0.5–2 mg), 20 with sustained‐release MLT (1–4 mg), and 12 taking a combination of them (same doses). Clinical variables and polysomnography were collected.
Results
Although clinical improvement was reported in all groups, MLT impacted sleep architecture more than the other treatments, with significant and large increase in N3 stage, moderate reduction in N2 and REM sleep, and moderate increase in REM latency. CLO moderately increased the percentage of both REM sleep and especially N2, while reducing N1 and wakefulness. Patients treated with both CLO and MLT did not show major changes in sleep architecture.
Conclusion
These results suggest that the administration of MLT or CLO impacts (positively) on sleep parameters of iRBD patients. However, there is a need to better stratify patients, in order to treat them in a targeted manner, depending on the patient's individual sleep architecture and expected differential effects of these agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vita-Salute San Raffaele University, Milan, Italy.
- Sleep Disorders Center, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
- Sleep Research Centre and Clinical Neurophysiology Research Unit, Oasi Research Institute - IRCCS, Troina, Italy.
- Department of Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy.
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
- Unit of Sleep Medicine and Epilepsy, IRCCS Mondino Foundation, Pavia, Italy.
ORCID-Profile: Maria P Mogavero, Raffaele Ferri, Sara Marelli, Giuseppe Lanza, Michele Terzaghi, Alessandra Castelnuovo, Lourdes M DelRosso, Carlos H Schenck, Luigi Ferini-Strambi
Förderung
- Ministero della Salute
Zitieren
APA
Mogavero, M. P., Ferri, R., Marelli, S., Lanza, G., Terzaghi, M., Castelnuovo, A., DelRosso, L. M., Schenck, C. H., & Ferini-Strambi, L. (2024). Polysomnographic features associated with clonazepam and melatonin treatment in isolated REM sleep behavior disorder: Time for new therapeutic approaches?. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14569
Vancouver
Mogavero MP, Ferri R, Marelli S, Lanza G, Terzaghi M, Castelnuovo A, et al. Polysomnographic features associated with clonazepam and melatonin treatment in isolated REM sleep behavior disorder: Time for new therapeutic approaches?. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14569
BibTeX
@article{Mogavero2024,
author = {Mogavero, Maria P and Ferri, Raffaele and Marelli, Sara and Lanza, Giuseppe and Terzaghi, Michele and Castelnuovo, Alessandra and DelRosso, Lourdes M and Schenck, Carlos H and Ferini-Strambi, Luigi},
title = {Polysomnographic features associated with clonazepam and melatonin treatment in isolated REM sleep behavior disorder: Time for new therapeutic approaches?},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14569}
}
EUVIMED